- Home
- CRGX vs INNV Comparison
CRGX vs INNV Comparison
Compare CRGX & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- INNV
- Stock Information
- Founded
- CRGX 2021
- INNV 2007
- Country
- CRGX United States
- INNV United States
- Employees
- CRGX N/A
- INNV N/A
- Industry
- CRGX
- INNV Medical/Nursing Services
- Sector
- CRGX
- INNV Health Care
- Exchange
- CRGX Nasdaq
- INNV Nasdaq
- Market Cap
- CRGX 964.5M
- INNV 817.8M
- IPO Year
- CRGX 2023
- INNV 2021
- Fundamental
- Price
- CRGX $12.81
- INNV $4.03
- Analyst Decision
- CRGX Strong Buy
- INNV Hold
- Analyst Count
- CRGX 6
- INNV 3
- Target Price
- CRGX $31.80
- INNV $6.00
- AVG Volume (30 Days)
- CRGX 229.0K
- INNV 56.4K
- Earning Date
- CRGX 11-12-2024
- INNV 02-04-2025
- Dividend Yield
- CRGX N/A
- INNV N/A
- EPS Growth
- CRGX N/A
- INNV N/A
- EPS
- CRGX N/A
- INNV N/A
- Revenue
- CRGX N/A
- INNV $786,512,000.00
- Revenue This Year
- CRGX N/A
- INNV $13.33
- Revenue Next Year
- CRGX N/A
- INNV $10.23
- P/E Ratio
- CRGX N/A
- INNV N/A
- Revenue Growth
- CRGX N/A
- INNV 12.46
- 52 Week Low
- CRGX $12.58
- INNV $3.52
- 52 Week High
- CRGX $33.92
- INNV $6.69
- Technical
- Relative Strength Index (RSI)
- CRGX 30.99
- INNV 30.89
- Support Level
- CRGX $13.33
- INNV $4.05
- Resistance Level
- CRGX $15.26
- INNV $4.93
- Average True Range (ATR)
- CRGX 1.36
- INNV 0.24
- MACD
- CRGX -0.30
- INNV -0.03
- Stochastic Oscillator
- CRGX 3.51
- INNV 19.66
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.